This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Neuralstem To Present Preclinical Data At Neuroscience 2012, 42nd Annual Meeting Of The Society For Neuroscience

ROCKVILLE, Md., Oct. 10, 2012 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced that it will present preclinical data in five poster presentations at Neuroscience 2012, the 42 nd Annual Meeting for the Society for Neuroscience., October 13-17, in New Orleans ( These posters will cover new data pertaining to Neuralstem's NSI-566 spinal cord stem cell line for cell therapy, and its patented, neurogenic small molecule compounds: NSI-144, NSI-150, NSI-158 and NSI-189. Abstracts of the poster are available at

(Logo: )

NSI-566 is in a Phase I trial to test the safety of the cells and procedure in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease). The last patient was treated in August, 2012. Neuralstem was recently approved to commence a NSI-566 trial in stroke in China, through its Chinese subsidiary, Neuralstem China, and has submitted an IND to the FDA to commence a trial in spinal cord injury with the same cells in the U.S.

NSI-144, NSI-150, NSI-158 and NSI-189 are small molecule, orally active compounds that stimulate new neuron growth in the hippocampus. NSI-189 is currently in a Phase Ib clinical trial testing its safety for the treatment of major depressive disorder (MDD).

The titles and schedule for Neuralstem's poster presentations at Neuroscience 2012 are:

  • "Survival and Differentiation of Human Neural Stem Cells (NSI-566RSC) After Grafting into Ischemia-Injured Porcine Brain," S.Wu et. al., University of California, San Diego, Poster #59.14/L20 - Saturday, October 13, 2:00-3:00, Hall F-J  
  • "Histopathological Assessment of Adult Ischemic Rat Brains After Intracerebral Transplantation of NSI-566RSC Cell Line," K.L. Hayama et. al., University of South Florida, Poster # 59.15/M1 - Saturday, October 13, 3:00-4:00, Hall F-J
  • "Decreased Tau Phosphorylation by AMPK Activation in Cortical Neurons," B. Kim et. al., University of Michigan, Poster # 220.08 - Sunday, October 14, 2:45-3:00, Location: 395 
  • "A Study to Examine the Tumorgenicity of Human Neural Stem Cell Line NSI-566RSC in Spinal Cord Injured Rats," T. Lam et. al., University of California, San Diego, Poster #450.17/K7 - Monday, October 15, 1:00-2:00. Hall F-J

NSI-144, NSI-150, NSI-158 and NSI-189
  • "Histological Assessment of Mouse Brains After 28-Day Chronic Oral Administration of Four Novel Neurogenic Compounds," D. Lee et. al, Poster # 664.20/X1 - Tuesday, October 16, 4:00 – 6:00, Hall F-J.

About Neuralstem

Neuralstem's patented technology enables the ability to produce neural stem cells of the human brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glia. Neuralstem has recently treated the last patient in an FDA-approved Phase I safety clinical trial for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig's disease, and has been awarded orphan status designation by the FDA.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury, ischemic stroke and glioblastoma (brain cancer). The company has submitted an IND (Investigational New Drug) application to the FDA for a Phase I safety trial in spinal cord injury.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,790.19 +13.76 0.08%
S&P 500 1,979.92 -7.13 -0.36%
NASDAQ 4,748.3610 -32.9030 -0.69%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs